Related Experiment Videos
ADHD and cardiometabolic risk profile in adults with type 2 diabetes: a longitudinal register-based study
Zihan Dong1, Shengxin Liu2, Cecilia Lundholm2
1Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden zihan.dong@ki.se.
Objective:
To investigate the association between attention-deficit/hyperactivity disorder (ADHD) and cardiometabolic risk profile at the time of type 2 diabetes (T2D) diagnosis and examine longitudinal changes in cardiometabolic measures following T2D diagnosis.
Design And Setting:
A nationwide cohort study using linked Swedish health registers.
Participants:
Adults aged 18-65 years with a first recorded diagnosis of T2D between 1996 and 2020. ADHD, treated as a lifetime condition, was identified through diagnostic and prescription records.
Outcome Measures:
The cardiometabolic risk profile, comprising nine clinical parameters and two behavioural factors, was assessed at T2D diagnosis and was tracked for up to 5 years post-diagnosis. Linear regression (βADHD) and Poisson regression models with robust variance (risk ratios (RRs)) compared cardiometabolic risk factors at diagnosis between individuals with and without ADHD. Generalised estimating equations (βADHD*t) assessed longitudinal changes in clinical parameters following the diagnosis.
Results:
Among 80 607 individuals with T2D, 1204 (1.5%) had an ADHD diagnosis. At T2D diagnosis, individuals with ADHD were younger and had statistically significantly higher body mass index (BMI) (βADHD: 1.93 (95% CI 1.54 to 2.32)), triglycerides (βADHD: 0.31 (95% CI 0.17 to 0.45)) and smoking prevalence (RR: 1.58 (95% CI 1.44 to 1.74)) compared with those without ADHD. Other cardiometabolic risk factors did not differ significantly. Over the subsequent 5 years, trajectories in cardiometabolic risk factors were broadly similar, except for a greater reduction in BMI in individuals with ADHD (βADHD*t: -0.26 (95% CI -0.34 to -0.17)), independent of baseline BMI and glucose-lowering medications. After inverse probability of treatment weighting, the BMI reduction was substantially reduced and not significant (βADHD*t: -0.05 (95% CI -0.17 to 0.07)).
Conclusions:
Among adults with newly diagnosed T2D, those with co-occurring ADHD had broadly similar cardiometabolic profiles to those without ADHD but presented at a younger age with a modestly higher BMI, triglycerides and smoking prevalence. Individuals with ADHD also showed a slightly greater reduction in BMI over time following T2D diagnosis. Despite modest overall cardiometabolic differences, incorporating ADHD status into preventive diabetes care may help identify a younger, more vulnerable subgroup who could benefit from targeted risk factor management.
Related Concept Videos
Type II Diabetes I: Introduction
Diabetes Mellitus: Type 2 and Gestational
Type II Diabetes II: Pathophysiology
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis
Diabetes: Symptoms, Diagnosis, and Complications
Attention-Deficit/Hyperactivity Disorder
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings.